In this study, we use high-dimensional phenotyping, transcriptional analysis, and plasma cytokine analysis to evaluate immune contexture in the peripheral blood of patients with advanced PDA being treated with CD40-based chemoimmunotherapy. The gene discussed is CD40; the disease is Patent ductus arteriosus.